2026 ACHONDROPLASIA & SKELETAL DYSPLASIA RESEARCH CONFERENCE • ORLANDO, FL
Press release from ABNewswire The Key Achondroplasia Companies in the market include – BridgeBio/ QED Therapeutics , Ribomic Inc, Sanofi, Changchun GeneScience Pharma, Ascendis Pharma A/S, QED Therapeutics, Inc, BioMarin…
Boero, Silvio & Vodopiutz, Julia & Maghnie, Mohamad & Bergua, Josep & Ginebreda, Ignacio & Kitoh, Hiroshi & Langendörfer, Micha & Leiva-Gea, Antonio & Malone, Jason & McClure, Philip &…
The Chandler Project was honored to be part of the task force that helped develop MyAchonJounrey.com, which launched today! My Achon Journey provides guidance on navigating medical topics, psychosocial issues,…
RIBOMIC Advances Pediatric Achondroplasia Treatment Study (via TipRanks Japan Auto-Generated Newsdesk • 8/2/24) “RIBOMIC Inc., a biopharmaceutical firm, has completed enrollment for its early Phase II study of umedaptanib pegol,…
SOURCE – Tyra Biosciences, Inc. – In a preclinical HCH model, TYRA-300 demonstrated increases in long bone length and binding against the HCH altered protein– -TYRA remains on track to submit ACH Investigational…
SOURCE: Bridge Bio, Inc. QED Therapeutics, an affiliate company of BridgeBio, is an Emerald Sponsor of this year’s Achondroplasia & Skeletal Dysplasia Research Conference, June 28-30 in Baltimore, Maryland. This…
